AgeX Therapeutics Past Earnings Performance
Past criteria checks 0/6
AgeX Therapeutics's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 59.9% per year.
Key information
-2.6%
Earnings growth rate
-1.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -59.9% |
| Return on equity | -276.4% |
| Net Margin | -10,424.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How AgeX Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -15 | 9 | 1 |
| 30 Sep 23 | 0 | -14 | 7 | 1 |
| 30 Jun 23 | 0 | -11 | 7 | 1 |
| 31 Mar 23 | 0 | -11 | 6 | 1 |
| 31 Dec 22 | 0 | -10 | 6 | 1 |
| 30 Sep 22 | 0 | -10 | 6 | 1 |
| 30 Jun 22 | 0 | -9 | 6 | 1 |
| 31 Mar 22 | 0 | -9 | 6 | 2 |
| 31 Dec 21 | 0 | -9 | 7 | 1 |
| 30 Sep 21 | 0 | -9 | 7 | 2 |
| 30 Jun 21 | 0 | -9 | 7 | 3 |
| 31 Mar 21 | 0 | -9 | 7 | 3 |
| 31 Dec 20 | 0 | -10 | 7 | 4 |
| 30 Sep 20 | 1 | -11 | 7 | 4 |
| 30 Jun 20 | 1 | -11 | 7 | 5 |
| 31 Mar 20 | 1 | -12 | 8 | 6 |
| 31 Dec 19 | 2 | -12 | 8 | 6 |
| 30 Sep 19 | 1 | -13 | 8 | 6 |
| 30 Jun 19 | 1 | -12 | 7 | 6 |
| 31 Mar 19 | 2 | -10 | 6 | 6 |
| 31 Dec 18 | 1 | -8 | 6 | 6 |
| 30 Sep 18 | 2 | -6 | 4 | 6 |
| 30 Jun 18 | 2 | -6 | 4 | 6 |
| 31 Mar 18 | 1 | -4 | 4 | 6 |
| 31 Dec 17 | 1 | -7 | 4 | 6 |
| 31 Dec 16 | 2 | -15 | 6 | 8 |
Quality Earnings: 0X40 is currently unprofitable.
Growing Profit Margin: 0X40 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0X40 is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.
Accelerating Growth: Unable to compare 0X40's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0X40 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).
Return on Equity
High ROE: 0X40 has a negative Return on Equity (-276.43%), as it is currently unprofitable.